# Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

> **NCT00697684** · PHASE1 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Acute Lymphocytic Leukemia
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Relapsed/Refractory Non Hodgkin's Lymphoma
- Hodgkins Disease
- Relapsed Refractory Multiple Myeloma

## Interventions

- **DRUG:** Antithymocyte Globulin
- **DRUG:** Clofarabine
- **DRUG:** Clofarabine
- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00697684
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2020-12
- **Final completion:** 2023-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697684, "Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00697684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*